Terms: = Cervical cancer AND KMT2D, ENSG00000167548, 8085, MLL2 AND Diagnosis
7 results:
1. Assessing the Genomic Landscape of cervical cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract] [Full Text] [Related]
2. Can we reduce dose to ureters as avoidance organs for MRI based brachytherapy for cervical cancer? A dosimetric feasibility study.
Koerner SA; Baig T; Kim H; Rodríguez-López J; Keller A; Beriwal S
Brachytherapy; 2022; 21(2):202-207. PubMed ID: 34980569
[TBL] [Abstract] [Full Text] [Related]
3. Basaloid Squamous Cell Carcinoma of the Uterine Cervix: Report of a Case With Molecular Analysis.
Munkhdelger J; Shimooka T; Koyama Y; Ikeda S; Mikami Y; Fukuoka J; Hori T; Bychkov A
Int J Surg Pathol; 2021 Oct; 29(7):770-774. PubMed ID: 33792431
[TBL] [Abstract] [Full Text] [Related]
4. Update of the genotype and phenotype of kmt2d and KDM6A by genetic screening of 100 patients with clinically suspected Kabuki syndrome.
Murakami H; Tsurusaki Y; Enomoto K; Kuroda Y; Yokoi T; Furuya N; Yoshihashi H; Minatogawa M; Abe-Hatano C; Ohashi I; Nishimura N; Kumaki T; Enomoto Y; Naruto T; Iwasaki F; Harada N; Ishikawa A; Kawame H; Sameshima K; Yamaguchi Y; Kobayashi M; Tominaga M; Ishikiriyama S; Tanaka T; Suzumura H; Ninomiya S; Kondo A; Kaname T; Kosaki K; Masuno M; Kuroki Y; Kurosawa K
Am J Med Genet A; 2020 Oct; 182(10):2333-2344. PubMed ID: 32803813
[TBL] [Abstract] [Full Text] [Related]
5. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
[TBL] [Abstract] [Full Text] [Related]
6. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract] [Full Text] [Related]
7. Oncogene expression and prognosis in cervical cancer.
Pillai R
Cancer Lett; 1991 Aug; 59(2):171-5. PubMed ID: 1884374
[TBL] [Abstract] [Full Text] [Related]
